# Trade Mark Journal No.2026/017 24 April 2026

## WO0000001911695 (5,42)

Office of origin: United States of America

Date of International Registration:6 March 2026
Date of designation in the UK: 6 March 2026

International priority date claimed: 13 February 2026 (United States of America) (99652396)
International priority date claimed: 13 February 2026 (United States of America) (99652403)

Class 5
  Pharmaceutical and biopharmaceutical drugs and medicines for treatment of degenerative retinal diseases.
Class 42
  Research and development of pharmaceutical and biopharmaceutical drugs and medicines for the treatment of degenerative retinal diseases; research and development in the pharmaceutical, life sciences and biotechnology fields.

Belite Bio, Inc.

Representative: Scott W. Pink O'Melveny & Myers, LLP, 2765 Sand Hill Rd, Menlo Park CA 94025-7019, UNITED STATES OF AMERICA